The Effects of Oral Lactocare® Administration on Gastrointestinal Disorders Caused by Chemotherapy in Children

Document Type : Original Article(s)

Authors

1 Instructor, Student Research Committee, Khomein University of Medical Sciences, AND Instructor, Department of Basic Sciences, Khomein University of Medical Sciences, Khomein, Iran

2 Associate Professor, Department of Pediatrics, Iran University of Medical Sciences, Tehran, Iran

3 Assistant Professor, Department of Pediatrics, Arak University of Medical Sciences, Arak, Iran

4 Medical Student, Department of Pediatrics, Iran University of Medical Sciences, Tehran, Iran

5 Assistant Professor, Department of Biochemistry and Genetics, Semnan University of Medical Sciences, Semnan, Iran

10.48305/jims.v41.i748.1109

Abstract

Background: Chemotherapy is one of the most common treatments for children with cancer, which is associated with gastrointestinal diseases. Synbiotics are supplements containing probiotics and prebiotics that potentially have a significant effect in modulating the intestinal microbiota.
Methods: This double-blind clinical trial was conducted on 88 children with non-hematological neoplasms. Patients were randomly divided into two groups to receive Lactocare® and placebo (46 patients in the Lactocare group and 42 patients in the placebo group). Patients receive the drugs twice a day for 14 days. The number of times diarrhea, vomiting, nausea, and constipation caused by chemotherapy were evaluated after the start of receiving Lactocare and placebo until the end of the study.
Findings: In the Lactocare® group, the duration of diarrhea and constipation (in days) after the first week was significantly less than in the placebo group (P < 0.05). There was no significant difference between the two groups in terms of the severity of nausea and vomiting (P > 0.05). The placebo group in our study was 1.37 times more likely to have diarrhea compared to the LactoCare®-treatment group (P = 0.041, odds ratio: 1.37; confidence interval: 1.05-3.31).
Conclusion: In this study, the use of Lactocare® reduced diarrhea and constipation caused by chemotherapy in patients. It seems that the use of Lactocare® synbiotic supplement is an easy and effective way to reduce diarrhea and constipation caused by chemotherapy in patients with neoplasms.

Highlights

Kazem Ghaffari: Google Scholar, PubMed

Aziz Eghbali: Google Scholar, PubMed

Atefeh Khalilpour: PubMed

Aygin Eghbali: PubMed

Ali Ghasemi: Google Scholar, PubMed

Keywords

Main Subjects

References

  1. Lavoie Smith EM, Kuisell C, Kanzawa-Lee GA, Bridges CM, Alberti P, Cavaletti G, et al. Approaches to measure paediatric chemotherapy-induced peripheral neurotoxicity: a systematic review. Lancet Haematol 2020; 7(5): e408-e417.
  2. Eghbali A, Ghaffari K, Khalilpour A, Afzal RR, Eghbali A, Ghasemi A. The effects of LactoCare synbiotic administration on chemotherapy‐induced nausea, vomiting, diarrhea, and constipation in children with ALL: A double‐blind randomized clinical trial. Pediatr Blood Cancer 2023; 70(6): e30328.
  3. Nurgali K, Jagoe RT, Abalo R. Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae? Front Pharmacol 2018; 9: 245.
  4. Eghbali A, Bagherloo T, Ghasemi A, Afzal RR, Eghbali A, Ghaffari K. The effect and safety of olanzapine on nausea and vomiting in children receiving moderately emetogenic chemotherapy. Adv Biomed Res 2023; 12: 158.
  5. Wenjie Y, Fuhua Y. Interpretation of the Clinical Practice Guidelines for Lung Cancer Screening (version 2) of 2022 National Comprehensive Cancer Network (NCCN). Journal of Diagnostics Concepts & Practice 2023; 22(01): 14-20.
  6. Turini M, Piovesana V, Ruffo P, Ripellino C, Cataldo N. An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries. Drugs Context 2015; 4: 212285.
  7. Eghbali A, Kohpar FK, Ghaffari K, Afzal RR, Eghbali A, Ghasemi A. Evaluating Aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: A triple-blinded randomized clinical trial. Hematol Transfus Cell Ther 2022; 45(3): 281-289.
  8. Bauters TGM, Verlooy J, Robays H, Benoit Y, Laureys G. Emesis control by aprepitant in children and adolescents with chemotherapy. Int J Clin Pharm 2013; 35(6): 1021-4.
  9. Sonis ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998; 34(1): 39-43.
  10. Ghaffari K, Sarlak S, Absalan A, Afzal RR, Eghbali A, Eghbali A. Dwindled serum IgG levels of Rubella, Diphtheria toxin, Hepatitis B virus and Tetanus Toxoid after chemotherapy; a report from Iranian children with malignancy. Iran J Ped Hematol Oncol 2022; 12(1): 1-9.
  11. Reyna-Figueroa J, Garcia-Beristain JC, Galindo-Delgado P, Limon-Rojas AE, Madrid-Marina V. Antibiotic use before chemotherapy: a risk factor for developing neutropenic colitis in children with leukemia. J Pediatr Hematol Oncol 2015; 37(2): 121-7.
  12. Zwielehner J, Lassl C, Hippe B, Pointner A, Switzeny OJ, Remely M, et al. Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting. PLoS One 2011; 6(12): e28654.
  13. Hadi A, Mohammadi H, Miraghajani M, Ghaedi E. Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD. Crit Rev Food Sci Nutr 2019; 59(15): 2494-505.
  14. Reyna-Figueroa J, Barrón-Calvillo E, García-Parra C, Galindo-Delgado P, Contreras-Ochoa C, Lagunas-Martínez A, et al. Probiotic supplementation decreases chemotherapy-induced gastrointestinal side effects in patients with acute leukemia. J Pediatr Hematol Oncol 2019; 41(6): 468-72.
  15. Hassan H, Rompola M, Glaser A, Kinsey SE, Phillips R. Systematic review and meta-analysis investigating the efficacy and safety of probiotics in people with cancer. Support Care Cancer 2018; 26(8): 2503-9.
  16. Wang YH, Yao N, Wei KK, Jiang L, Hanif S, Wang ZX, et al. The efficacy and safety of probiotics for prevention of chemoradiotherapy-induced diarrhea in people with abdominal and pelvic cancer: a systematic review and meta-analysis. Eur J Clin Nutr 2016; 70(11): 1246-53.
  17. Waheed A, Malone M, Samiullah S. Functional Gastrointestinal Disorders: Functional Gastrointestinal Disorders in Children. Gut 2018; 466: 29-35.
  18. Kim AR, Cho J, Hsu YJ, Choi MG, Noh JH, Sohn TS, et al. Changes of quality of life in gastric cancer patients after curative resection: a longitudinal cohort study in Korea. Ann Surg 2012; 256(6): 1008-13.
  19. Linn YH, Thu KK, Win NHH. Effect of probiotics for the prevention of acute radiation-induced diarrhoea among cervical cancer patients: a randomized double-blind placebo-controlled study. Probiotics Antimicrob Proteins 2019; 11(2): 638-47.
  20. Wardill HR, Van Sebille YZ, Ciorba MA, Bowen
    Prophylactic probiotics for cancer therapy-induced diarrhoea: a meta-analysis. Curr Opin Support Palliat Care 2018; 12(2): 187-97.
  21. Asadi M, Fazeli MR, Sabokbar A. Growth Inhibitory Effect of Lactocare on Vibrio cholerae. Iran J Pathol 2018; 13(3): 301-7.
  22. Urbancsek H, Kazar T, Mezes I, Neumann K. Results of a double-blind, randomized study to evaluate the efficacy and safety of Antibiophilus® in patients with radiation-induced diarrhoea. Eur J Gastroenterol Hepatol 2001; 13(4): 391-6.
  23. Wang B, Mao YK, Diorio C, Pasyk M, Wu RY, Bienenstock J, et al. Luminal administration ex vivo of a live Lactobacillus species moderates mouse jejunal motility within minutes. FASEB J 2010; 24(10): 4078-88.
  24. Dimidi E, Scott SM, Whelan K. Probiotics and constipation: mechanisms of action, evidence for effectiveness and utilisation by patients and healthcare professionals. Proc Nutr Soc 2020; 79(1): 147-57.
  25. Mazziotta C, Tognon M, Martini F, Torreggiani E, Rotondo JC. Probiotics mechanism of action on immune cells and beneficial effects on human health. Cells 2023; 12(1): 184.
  26. Martin IW, Tonner R, Trivedi J, Miller H, Lee R, Liang X, et al. Saccharomyces boulardii probiotic-associated fungemia: questioning the safety of this preventive probiotic's use. Diagn Microbiol Infect Dis 2017; 87(3): 286-8.
  27. Guandalini S. Probiotics for children with diarrhea: an update. J Clin Gastroenterol 2008; 42 (Suppl 2): S53-7.
  28. Depoorter L, Vandenplas Y. Probiotics in pediatrics. A Review and Practical Guide. Probiotics 2022:
    425-50.
Journal of Isfahan Medical School
Volume 41, Issue 748
4th Week, February
January and February 2024
Pages 1109-1117

Files

History

  • Receive Date: 23 August 2023
  • Accept Date: 26 February 2024

Share

How to cite

Statistics